Immutep S.A. and Eddingpharm have entered an agreement for the development, commercialization, and manufacture of Immutep’s ImmuFact IMP321 in China. The companies plan to develop the product for first-line metastatic breast cancer, as well as other first-line metastatic indications. Financial details were undisclosed but include milestone payments and royalties. Burrill Securities acted as financial advisor for the transaction.   The agreement grants Eddingpharm exclusive rights to develop and ...